



Chronic Malignancies Working Party

CML & MDS & PH-neg MPN

Activities of the working party and subcommittees


Chair: Ibrahim Yakoub-Agha

Secretary: Patrick Hayden

Email address: cmwpebmt@lumc.nl

Subcommittee Chronic Myeloid Leukemia (CML)

Chair: Yves Chalandon



Data Quality Initiative (DQI)

Fifty-four centers, comprising 702 patients, have participated in the CML Data Quality Initiative. The data will be utilized for various studies in the future.

Studies starting soon

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic HSCT - *Hugues de Lavallade*

Outcome Unrelated CB transplantation in patients with CML - *Hugues de Lavallade*

Prognostic value of additional cytogenetic abnormalities at transplantation in CML patients - *Jo Caers*

Post-Transplant Scoring System for CML Based on Retrospective Analysis of Patients Surviving more than 100 Days after Allo-HSCT - *Maria Mappoura & Yves Chalandon*

Monday March 21st, 2022 – South Hall 1A+B / Virtual Hall 4


Oral session 3: Various diseases: myeloproliferative neoplasms and myelodysplastic syndrome

16:33 – 16:42 OS03-03 Unrelated and haploidentical donor allo-HCT for CML with post transplant cyclophosphamide as GvHD prophylaxis: a study from the Chronic Malignancies Working Party of the EBMT – *Ortí et al.*

17:09 – 17:18 OS03-07 Allogeneic transplantation for PH+ Chronic Myeloid Leukemia: a retrospective analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP) comparing outcomes according to donor type – *Onida et al.*

Subcommittee Myelodysplastic Syndromes (MDS)

Chair: Marie Robin, Vice-chair: Christof Scheid, CMML: Francesco Onida



Ongoing data request

Comparison between PT-Cy-based vs other GvHD Prophylaxis in Matched Related Donor allogeneic HSCT for MDS patients – *Maria Queralt Salas & Jordi Esteve*

Recently started

Allogeneic stem cell transplantation for MDS patients with VEXAS syndrome: a joint study from the Chronic Malignancies Working Party and Autoimmune Diseases Working Party of the EBMT – *Carmelo Gurnari*

Step 1: retrospective study on patients with MDS/VEXAS co-diagnosis undergone HSCT across EBMT centres.

Step 2: prospective non-interventional observational study to investigate the role of HSCT in patients with VEXAS and MDS dyad as to the clinical outcomes of both MDS and VEXAS.


Monday March 21st, 2022 – South Hall 1A+B / Virtual Hall 4

Oral session 3: Various diseases: myeloproliferative neoplasms and myelodysplastic syndrome

17:18 – 17:27 OS03-08 Allogeneic hematopoietic stem cell transplantation for Myelodysplastic Syndrome Unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – *Drodz-Sokolowska et al.*

Subcommittee PH-neg Myeloproliferative Neoplasms (MPN)

Chair: Donal McLornan, Vice-chair: Juan Carlos Hernández-Boluda, Tomasz Czerw



Upcoming data requests

A retrospective analysis of transplantation outcome for individuals with Advanced Systemic Mastocytosis (Adv-SM): Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematologic Disease (SM-AHD), Mast-Cell Leukemia (MCL) and Mast Cell Sarcoma (MCS) – *Ghandi Damaj*

Systemic mastocytosis (SM) is a clonal hematological disorder of mast cells (MCs) characterized by increased MC burden, with focal and/or diffuse infiltrates of neoplastic MCs in skin, bone marrow (BM), spleen, liver, gastrointestinal (GI) tract, and other organs, and increased release of MC mediators.

Allogeneic SCT (allo-SCT) may benefit some patients. In the largest study reported today, 57 patients receiving alloHCT in the United States and Europe (Ustun 2016). Although this study provides critical insight into understanding the efficacy and safety of alloHCT in advanced SM, many questions remain to be answered.

We propose to analyze patients with Adv-SM from the EBMT data base to better understand some questions and contribute to better management of this rare and aggressive diseases

Impact of CD34+ cell grafts content on clinical outcomes after family mismatched allo-HCT for myelofibrosis - *Tomasz Czerw*

Cellular composition of grafts is believed to be one of the significant determinants of outcomes of allo-HCT. However, published observations have reported unequivocal conclusions with regards to post-transplant outcomes which may in part result from the heterogeneity of the study populations. The aim of this study will be to determine a potential impact of the number of transplanted CD34+ cells on post-transplant clinical outcomes in MF patients transplanted from family mismatched donors.

Ongoing studies

Treosulfan in conditioning regimen before allogeneic HSCT in myelofibrosis patients – *Marie Robin*

Post-Transplant Cyclophosphamide as GvHD Prophylaxis for Allogeneic Hematopoietic Stem Cell Transplantation for myelofibrosis as compared to standard GvHD prophylaxis: A CMWP Study – *Yves Chalandon*

Prevalence of liver toxicity in the early post-transplant period in patients with myelofibrosis: a retrospective study on behalf of the CMWP of EBMT study – *Marie Robin*

Risk factors allogeneic HSCT in patients with CALR-mutated myelofibrosis – *Juan Carlos Hernández-Boluda*

Monday March 21st, 2022 – South Hall 1A+B / Virtual Hall 4

Oral session 3: Various diseases: myeloproliferative neoplasms and myelodysplastic syndrome

16:15 – 16:24 OS03-01 Allogeneic hematopoietic cell transplant for blast phase of Philadelphia-chromosome negative myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT – *Ortí et al.*

16:24 – 16:33 OS03-02 Outcomes of allogeneic hematopoietic cell transplantation for Chronic Neutrophilic Leukemia: a combined CIBMTR/EBMT analysis – *Dholaria et al.*

17:00 – 17:09 OS03-06 Outcome of allogeneic haematopoietic cell transplantation in Eosinophilic disorders: a retrospective study by the Chronic Malignancies Working Party – *McLornan et al.*

Chronic Malignancies Working Party Session EBMT 2022

Monday March 21st, 2022 10:45 – 12:00

Congress Hall / Virtual Hall 1

10:45 – 11:10 One year of VEXAS: what we know and where we are going *Carmelo Gurnari*

11:10 – 11:35 Blast phase MPN – new developments *Guillermo Ortí*

11:35 – 12:00 EBMT scoring system for early relapse after auto-HCT in MM patients *Meral Beksac*

Chronic Malignancies Working Party Business Meeting EBMT 2022

Monday March 21st, 2022 7:00 – 08:50

Location: South Hall 1A+B / Virtual Hall 4